Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin

A vancomycin, aerosolization technology, which can be used in therapeutic nebulizers, drug combinations, drug delivery, etc., and can solve problems such as harmful health effects

Inactive Publication Date: 2010-10-27
NOVARTIS AG
View PDF31 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This can ultimately allow individuals in the vicinity of the patient to passively administer the drug, exposing them to the risk of adverse health effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
  • Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
  • Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0097] As noted above, conventional nebulizer-ventilator systems have low drug delivery efficiencies (eg, less than 20%). Embodiments of the invention include methods and systems that increase delivery efficiency to, for example, at least 25%, or at least 30%, or at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or more. The increased efficiency in delivering aerosolized drugs may be due in part to one or more features that may be applied in embodiments of the invention. These features include synchronizing the generation of aerosol with the inhalation phase of the ventilator cycle (eg, staged delivery). These features may also include supplying air (eg, "air flow") following the generation of the aerosol, which can clean the endotracheal tube and reduce the amount of drug exhaled by the patient. These features may further include a hub connecting the aerosol generating unit directly to an endotracheal tube connected to the patient. Other features include...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
surface tensionaaaaaaaaaa
diameteraaaaaaaaaa
elastic modulusaaaaaaaaaa
Login to View More

Abstract

A method of administering an aerosolized anti-infective, such as a glycopeptide, to the respiratory system of a patient. A ratio of an amount of the glycopeptide, such as vancomycin, delivered to the pulmonary system of the patient in a 24 hour period to a minimum inhibitory amount for the target organ for the same period is about 2 or more. A system to introduce aerosolized medicament to a patient may include a humidifier coupled to an inspiratory limb of a ventilator circuit wye, where the humidifier supplies heated and humidified air to the patient, and an endotracheal tube having a proximal end coupled to a distal end of the ventilator circuit wye. The system may also include a nebulizer coupled to the endotracheal tube, where the nebulizer generates the aerosolized medicament.

Description

[0001] Cross References to Related Applications [0002] This application claims priority and is a continuation-in-part of US Patent Application US 60 / 975,094, filed September 25, 2007. [0003] This application claims priority and is a continuation-in-part of US patent application US 11 / 654,212, filed January 16, 2007. US 11 / 654,212 is a continuation-in-part of US patent application US 11 / 090,328 filed March 24, 2005. US 11 / 090,328 is a continuation-in-part of US 10 / 345,875 filed January 15, 2003. [0004] This application additionally claims priority and is a continuation-in-part of US Patent Application US 10 / 284,068, filed October 30, 2002. US 10 / 284,068 claims the benefit of US 60 / 344,484, filed November 1, 2001, and US 60 / 381,830, filed May 20, 2002. The entire contents of all the above-mentioned documents are incorporated herein. [0005] This application is also related to US patent applications US 2002-0134375, US 2002-0134374, US patents US 6,948,491, US 6,615,824,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K38/14A61M15/00
CPCA61M2015/0015A61K38/14A61M2015/0083A61M16/0816A61M2230/40A61M2205/3389A61M2209/02A61M15/0085A61M11/005A61M2015/0018A61M2016/0027A61M2016/0021A61M2205/3375A61M2016/0039A61M2016/0833A61M2016/1065A61M15/0086A61M2205/7518A61M2016/107A61K9/0078A61M2015/0016A61M16/16A61M16/0833A61M15/0015A61M15/0016A61M15/0018A61M15/0083A61M16/1065A61M16/107A61M16/0858A61P1/16A61P11/08A61P19/04A61P31/04A61P31/10A61P31/12A61P33/02A61P9/08
Inventor N·P·卡德里库J·B·芬克
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com